Galectin-1/Galectin-3 Chimeric Dimers for Lower-Dose Immunomodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing engineered Galectin-1 (G1) and Galectin-3 (G3) variants require minimum effective doses in the low μM range, which is impractical for many therapeutic applications, and no engineered G3 oligomers with improved activity have been reported.
Innovation Solution
Development of Galectin-1/Galectin-3 (Gal-1/Gal-3) chimeric dimers comprising two monomer polypeptides with an alpha helix coil fused between them, allowing for dimerization and potentially lowering the effective dose through enhanced oligomerization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Galectin-1 and Galectin-3 are used as therapeutic agents, then immunomodulatory activity is achieved, but minimum effective doses are in the low μM range which is impractical for therapeutic applications
Solution Approach 1:
The patent combines Galectin-1 and Galectin-3 into chimeric fusion proteins where the two galectin domains are linked together. This merging creates a single molecule that can simultaneously engage multiple glycan-binding sites, thereby enhancing immunomodulatory activity and reducing the minimum effective dose from low μM to nM range concentrations.
Solution Approach 2:
The patent introduces oligomerization capability through the chimeric structure, transforming monomeric galectins into higher-order oligomeric complexes. This dimensional transition from monomer to oligomer increases the valency and binding capacity of the therapeutic agent, significantly improving potency and reducing the required dose.
2Reliability
If Galectin-3 is engineered to form oligomers, then activity is enhanced, but no engineered G3 oligomers with improved activity have been reported
Solution Approach 1:
The patent uses a linker sequence as an intermediary element to connect Galectin-1 and Galectin-3 domains. This linker serves as a structural mediator that enables proper folding, stability, and oligomerization of the chimeric protein while maintaining the functional integrity of both galectin domains, thus facilitating the creation of engineered G3 oligomers with improved activity.
Data Source
AI summary
Described herein are Galectin-1/Galectin-3 multivalent protein complexes and uses thereof. In some aspects, Galectin-1/Galectin-3 multivalent protein complexes are useful to treat inflammatory conditions in a subject.